Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Improvements of the Smart Pulse Technology to epi-LASEK outcomes

Poster Details

First Author: M. Camellin ITALY

Co Author(s):    S. Mosquera                    

Abstract Details


evaluate the clinical outcomes of the Smart Pulse Technology applied to epi-LASEK corrections with the SCHWIND AMARIS.


DR. Massimo Camellin, Sekal Rovigo Microsurgery Centre, Rovigo, Italy


32 eyes treated in epi-LASEK with the SCHWIND AMARIS Smart Pulse Technology have been retrospectively compared to a historic cohort of 32 matched eyes previously treated in epi-LASEK with the SCHWIND AMARIS ( without Smart Pulse Technology).


Smart Pulse Technology shows improved UDVA outcomes compared to previous epi-LASEK from Day 1 (4 lines better) to 1 month (0,5 lines better) postoperatively (p<0.05). At day 1 postoperatively, 66% of the Smart Pulse Technology treatments reach 20/40 or better, vs. only 17% of the previous epi-LASEK. Results become equivalent at 3 months (p>0.05).UDVA at Day 1 postoperatively averaged 0.28±0.19logMAR for Smart Pulse Technology and 0.64±0.21logMAR for the original AMARIS epi-LASEK (p<0.01). Postoperative Refractionsare similar (p>0.05) and excellent in both groups (mean SE +0.1±0.2D; mean Ast 0.3±0.3D).


SmartSurfACE offers clear superiority in terms of visual recovery (CDVA and UDVA) for the short term (up to 1 month postoperatively) compared to the original AMARIS epi-LASEK.The short term superiority could be attributed to the improved residual roughness (enhanced smoothness) of the corneal surface.

Financial Disclosure:


Back to Poster listing